Alterity Therapeutics ( (ATHE) ) just unveiled an announcement.
Alterity Therapeutics announced on March 27, 2025, the completion of the last patient visit in its ATH434-202 open-label Phase 2 trial for advanced multiple system atrophy (MSA). This study aims to evaluate the safety, efficacy, and target engagement of ATH434, a drug candidate targeting Parkinsonian disorders. The trial enrolled 10 participants who received ATH434 treatment over 12 months, focusing on neuroimaging and protein biomarkers. The results, expected mid-2025, will guide further development of ATH434, which has shown promise in earlier trials and holds Orphan Drug Designation from the U.S. FDA and European Commission.
More about Alterity Therapeutics
Alterity Therapeutics is a clinical stage biotechnology company focused on developing disease modifying therapies for neurodegenerative diseases, particularly Parkinson’s disease and related disorders. The company is headquartered in Melbourne, Australia, and San Francisco, USA, and is engaged in drug discovery to treat neurological diseases.
YTD Price Performance: -4.56%
Average Trading Volume: 493,866
Technical Sentiment Signal: Sell
Current Market Cap: $37.72M
For an in-depth examination of ATHE stock, go to TipRanks’ Stock Analysis page.